Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?

Paolo Carlini, Gianluigi Ferretti, Serena Di Cosimo, Elvira Colella, Riccardo Tonachella, Adriana Romiti, Silverio Tomao, Antonio Frassoldati, Paola Papaldo, Alessandra Fabi, Enzo Maria Ruggeri, Francesco Cognetti

Research output: Contribution to journalArticlepeer-review

Abstract

To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane. In 19 out of 21 patients (90.5%), a clinical benefit response was achieved by anastrozole, with a median duration of 12 months. Out of the 21 women progressing on anastrozole, 12 achieved stable disease (SD)≥6 months by formestane only. The overall clinical benefit was 66.5%. The median duration of clinical benefit was 11 months with a time to progression of 6.5 months. The median duration of clinical benefit in our series is similar to that reported in two phase II trials with the sequence aminogluthetimide→formestane and aminogluthetimide→exemestane as third-line hormonal therapy, suggesting a non-cross-resistance between the two classes of inhibitors.

Original languageEnglish
Pages (from-to)107-109
Number of pages3
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume86
Issue number1
DOIs
Publication statusPublished - Jul 2003

Keywords

  • Anastrozole
  • Formestane
  • Postmenopausal metastatic breast cancer (PMBC)

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Fingerprint Dive into the research topics of 'Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?'. Together they form a unique fingerprint.

Cite this